Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
The goal of the proposed study is to evaluate the safety and feasibility of oral Glutathione in children and adolescents who have Autism Spectrum Disorder. Twenty-four subjects with ASD will receive 12 weeks of oral Glutathione reduced. The hypothesis to be tested is that: Oral Glutathione will be effective in increasing the blood level of Glutathione, which may help to decrease some problem behaviors and irritability in this particular ASD population. The second aim of this study is to evaluate the tolerability of oral Glutathione. The proposed study may provide needed data for future studies aimed at the treatment of aggressive behaviors that can be seen in this patient population.
Age
4–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Boys and girls ages 4-17
Current diagnosis of Autism Spectrum Disorder as determined by criteria in DSM-5
Parents of Children ages 4-17 with a current diagnosis of Autism Spectrum Disorder as determined by criteria in DSM-5
You may not be if
Unstable medical illness or clinically significant abnormalities on physical examination;
History of seizures;
History of Hematological disorders;
Myocardial infarction within 6 months;
Current pregnancy or lactation, or inadequate contraception in girls of childbearing potential;
Current or recent (past 3 months) DSM-5 substance abuse or dependence;
Illegal substance use within 2 weeks of study initiation;
Previous treatment with Glutathione;
Current treatment with N-acetylcysteine, milk thistle, Vitamin C, Vitamin B, Grape Seed Extract, Amino Acids, or Zinc
Current treatment with Dextromethorphan, D-cycloserine, Amantadine, Memantine, Lamotrigine or Riluzole
Asthma
Clareo Health | A Study of Glutathione in Children With Autism Spectrum Disorder
